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ABSTRACT
Opioid misuse remains at epidemic proportions in the United States and other countries.
Buprenorphine has been found effective in treating opioid use disorder (OUD). Understanding
the roles of personal characteristics and readiness to change in addiction treatment retention and
quality of recovery could be beneficial in office-based medication-assisted treatment for OUD.
Researchers have explored OUD treatment methods and outcomes and have examined various
predictive factors in treatment results, including demographic, socioeconomic, and psychological
variables. However, few characteristics have been found to be consistent indicators of treatment
retention and recovery quality. The constructs of hope agency, hope pathways, grit, and
readiness to change as predictors of treatment retention and recovery quality in office-based
OUD programs and how these constructs relate to clinical application and future research were
examined in this study. Data analysis indicated that hope agency, hope pathways, and grit were
predictive of recovery quality but not of treatment retention. Readiness to change was not
predictive of recovery quality or retention. The clinical implication is that identifying predictive
personal characteristics can lead to enhanced treatment planning and better treatment outcomes.
As a pilot study, the sample size was too small to establish statistical significance. However,
these findings contribute to OUD treatment literature and highlight the need for additional
research in this area, possibly validating these findings in larger populations.
Keywords: buprenorphine, hope, grit, readiness to change, opioid, recovery, treatment
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CHAPTER ONE: INTRODUCTION
Drug addiction has been a significant health problem in the United States for decades,
and for centuries in other countries (Springer et al., 2019; Pecoraro et al., 2012). Drug overdose
death rates in the United States more than doubled from 1999 to 2016 in all age groups and
among both males and females (Hedegaard et al., 2017). A dramatic increase in opioid abuse,
including synthetic opioids and prescription pain medication, has contributed to the steady rise in
these rates. Opioid use disorder (OUD) has emerged as a major issue in the United States as
opiate-related overdose rates have soared to record highs (MacDonald et al., 2016). The National
Institute on Drug Abuse (NIDA; 2018) reported that a staggering 115 Americans die every day
as a result of an opioid overdose.
Research has shown opioid addiction to be treatment resistant (Molfenter et al., 2015;
Nosyk et al., 2015), but some treatments are providing encouraging outcomes. Opioid
substitution treatment has been shown to be safe and effective in reducing illicit opioid use in
some cases, improving physical and mental well-being, and reducing overdose death rates (Sordo
et al., 2017). Findings from several large clinical studies indicated that buprenorphine and a
buprenorphine/naloxone combination are effective in helping individuals discontinue opiate use
(Hser et al., 2014) and enjoy a higher quality of life (Öhlin et al., 2015). Buprenorphine differs
from methadone maintenance therapy (which must be conducted in a highly structured clinic) in
that it can be prescribed in office-based practices, significantly increasing treatment access. Even
with enhanced medication-assisted treatment (MAT), patients with OUD often require multiple
treatment attempts before achieving stable recovery (Unger, 2017). Disengagement rates are
highest in the first 30 days of treatment, and return to use rates can be as high as 90% (Hui et al.,
2017). Identifying these higher risk patients and addressing issues in treatment planning could
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improve treatment retention. People who remain engaged in treatment are less likely to relapse
and more likely to achieve longer term recovery (Hui et al., 2017; Socías & Ahamad, 2016).
Treatment retention and effectiveness may be associated with individual characteristics
such as grit (Griffin et al., 2016), hope (Corrigan et al., 2017), and readiness to change
(DiClemente, 2003). Identifying levels of these traits at treatment outset may predict higher or
lower retention rates as well as steer prescribers and clinicians in specific areas of treatment
focus.
Background of the Problem
Opioid analgesics have been used to treat acute pain as far back as the 3rd century BC,
according to ancient medical texts from Mesopotamian archeological discoveries (Pecoraro et
al., 2012). Opium was introduced to India and China by the 8th century, and then into Europe
after the 10th century. Documentation regarding addiction and tolerance was discovered in 16thcentury Egypt, so this problem has endured for the last 500 years at least (Pecoraro et al., 2012).
Opium was introduced in the United States in the late 1800s, but smoking opium was
stigmatized as a Chinese practice. Morphine was used in the Civil War as a pain medication and
was more widely accepted as medicinal and even recreational (Pecoraro et al., 2012). As
morphine dependence increased, heroin was developed as a nonaddictive cure for morphine
abuse and an over-the-counter cough medicine. Heroin was soon found to be more addictive than
morphine, and it became the illicit drug of choice in America in the early 1900s. Heroin’s
recreational use has continued despite its well-known addictive and treatment-resistant nature
(Dart et al., 2015; Streltzer et al., 2015). Opioid abuse has continued to be a problem in many
countries (Vowles et al., 2015). Public health issues regarding opioid addiction and related
overdose deaths have reached epidemic proportions globally (Dart et al., 2015). Prescription
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opioid medication use has increased greatly in the United States since the early 2000s, further
fueling the widespread abuse into smaller towns until the nation seemed saturated with opioid
addiction and all of the related negative social and economic effects that follow (Main & Kelly,
2016; Springer et al., 2019).
Purpose of the Study
The purpose of this study was to examine the association of personal characteristics of
hope, grit, and readiness to change and retention in office-based opioid MAT. The personal
characteristics of grit, hope, and readiness to change were measured to determine their predictive
strength in successful recovery in medication-assisted office-based buprenorphine programs. If
the relationships among these variables are more clearly understood, future treatment plans and
research involving substance abuse treatment could be better informed. The study goal was to
determine if individuals with higher baseline scores on measures of grit, hope, and readiness to
change at treatment outset are better able to successfully remain in MAT than those with lower
scores on those baseline measurements.
Research Hypotheses
There were two hypotheses in this study. The first research hypothesis was that hope,
grit, and readiness to change levels for individuals entering office-based buprenorphine programs
are associated with quality of recovery scores. The second hypothesis was that there is an
association between hope, grit, and readiness to change scores with retention in treatment.
The first null hypothesis was that there is no association between hope, grit, and readiness
to change scores and treatment retention. The second null hypothesis stated that there is no
association between hope, grit, and readiness to change scores and quality of recovery scores.
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The dependent variables were treatment retention and quality of recovery. The independent
variables were hope scores, grit scores, and readiness to change scores.
Assumptions and Limitations
Limitations in this study decreased generalizability to certain populations. Participant
selection was limited to individuals seeking treatment for OUD; as such, study results may not
translate to the general population or those seeking treatment for other addictive and cooccurring
mental health issues. Also, each office-based buprenorphine program may have different
guidelines and procedures regarding frequency of appointments, drug screens and policies, etc.
that can affect retention and perceived quality of recovery. This study only generalizes to a
population that is similar to that represented in this study.
Measures used to gather data on the study’s independent variables were self-report
instruments and may only be accurate to the extent that the individuals understood the questions
and provided honest answers. Also, quality of recovery as expressed by each participant must be
comparatively measured with some understood variability. The power of this study was limited
by the availability for new patients in these office-based programs as well as the limited length of
time committed for the trial.
Definition of Terms
The following terms were defined from recent and relevant research to provide clarity for
this study.
Addiction: Addiction can be viewed as a chronic but treatable mental condition that
produces dependence (usually pharmacological) and eventual self-destructive behavior (Pecoraro
et al., 2012). DiClemente (2018) identified three necessary components to define addiction: (a) a
fully established pattern of problematic pleasurable and reinforcing behavior; (b) dependence is
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present with psychological and physiological dimensions; and (d) the interactions of these
elements make the behavior important to the individual and very resistant to change.
Buprenorphine: Buprenorphine is an opioid partial agonist that produces effects such as
euphoria or respiratory depression. With buprenorphine, however, there is a ceiling effect that
makes the opiate effect weaker than methadone (and other full opiate agonists such as heroin,
morphine, etc.), reducing the risk of misuse and level of impairment (MacDonald et al., 2016).
Naloxone can be combined with buprenorphine to form a compound to dissuade misuse and
diversion of buprenorphine by injection. Naloxone is more effective in blocking the opioid effect
when injected, and studies have indicated that buprenorphine can be prescribed with less
supervision and risk of abuse (Lobmaier et al., 2010).
Grit: Grit is defined as a higher order personality trait with primary components of
perseverance of effort and consistency of interest (Credé et al., 2017). Duckworth (2016)
presented grit as a process of developing the skill for a desired goal, and through sustained
deliberate effort, achieving the goal by mastering the process. She stated:
To be gritty is to keep putting one foot in front of the other. To be gritty is to hold fast to
an interesting and purposeful goal. To be gritty is to invest, day after week after year, in
challenging practice. To be gritty is to fall down seven times, and rise eight. (p. 275)
Grit from a substance use treatment perspective can be to maintain perseverance and focused
motivation to not give up despite obstacles to the goal (Griffin et al., 2016).
Hope: Hope can be defined as a perception that goals can be achieved. Having positive
thoughts and goal-directed activities play important roles in the subsequent achievement of
positive outcomes (Snyder et al., 1996). Hope is being able to overcome obstacles to goals and
continue with optimism. Snyder (2002) posited that hope can be divided into the two
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components of agency and pathways. Agency can be understood as will power to stay the course
to reach a goal, and pathways is to make a way or path to achieve a goal (May et al., 2015). Hope
has been positively associated with self-esteem, physical and mental health, and positive affect
as well as reduced anxiety, depression, and negative general affect (Brouwer et al., 2008).
Medication-assisted treatment (MAT): The Substance Abuse and Mental Health Services
Administration (2020) defines MAT as using Food and Drug Administration-approved
medications with counseling and behavioral therapies to treat substance use disorders and
prevent opioid overdose.
Office-based treatment: Office-based treatment refers to prescribing buprenorphine in a
primary care/general practice physician setting as opposed to a clinic or treatment center. Visit
frequency can be extended to where an individual may only have to report to the prescriber on a
monthly basis versus daily or a couple of times each week. This allows the patient to engage in
“normal life” activities such as full-time employment (Hui et al., 2017).
Opioid use disorder (OUD): OUD can be defined as a problematic pattern of opioid use
resulting in significant impairment and distress at a clinical level (American Psychiatric
Association, 2013).
Readiness to change: In the scope of addiction treatment, readiness to change can be
defined as an individual’s current motivation and influences for engaging and continuing in
treatment despite physiological and psychological dependence (DiClemente, 2003; DiClemente
et al., 2004). Readiness to change takes into consideration personal reasons, experiences, and
circumstances involved in deciding to contemplate or be willing to change.
Recovery: Recovery can be defined as a sustained process through which individuals,
families, and communities impacted by addiction use all available resources to purposefully
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solve the problems, actively manage vulnerability and inevitable temptation to reengage the
behavior, and intentionally develop a productive and healthy lifestyle absent of the prior
maladaptive behavior (el-Guebaly, 2012). The Betty Ford Institute Consensus Panel (2007)
referred to recovery as a “voluntarily maintained lifestyle characterized by sobriety, personal
health, and citizenship” (p. 221). Improvement in overall quality of life is also a major
component of recovery.
Remission: Remission is defined as a sustained period of time without substance use
problems (Peele, 2000). The fifth edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5; American Psychiatric Association [APA], 2013) classifies early remission as
3–12 months and sustained remission as 12 months and longer. Being able to maintain focus and
engagement in a healthy and productive life is a component of remission (Peele, 2000).
Significance of the Study
As opioid-related overdose deaths continue to rise, treatment effectiveness is increasingly
important. Several large clinical studies have shown buprenorphine effective in helping
individuals discontinue opiate use (DeMaria & Risler, 2012) and lead stable and productive lives
(Unger, 2017). Findings from the present study may add a layer of understanding to pretreatment
predictors for treatment retention, and treatment retention is a key element in successful recovery
(Tkacz et al., 2012). Improved knowledge of individual characteristics that predict treatment
success can lead to more effective treatment planning for practitioners who work with this
population. For example, if a client enters treatment with a deficit in any of the predictive
categories, the required psychosocial treatment plan could be tailored to improve that particular
element for that client. Additional support and counseling could be specifically targeted to help
those who are at higher risk for lower treatment retention rates (Lee et al., 2017). This
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pretreatment predictor research may possibly be generalized to treatments for other substance use
disorders.
Theoretical and Conceptual Framework
An abundance of research indicates that OUD can be categorized as a worldwide health
care problem, particularly in the United States where this condition has reached epidemic
proportions (Streltzer et al., 2015). Addiction problems and overdose deaths continue to rise
throughout the United States, affecting big cities and small towns alike. MAT has been found to
provide some encouraging results in helping opioid dependent individuals achieve a level of
abstinence and recovery (Soyka, 2013; Springer et al., 2019).
Opiate replacement medications such as methadone and buprenorphine are currently most
often prescribed and seem most effective in helping individuals stay in treatment and reduce
illicit opiate use (Blum et al., 2016; Griffin et al., 2014). When used to treat OUD, methadone is
most often administered in a daily clinic setting and must be monitored more carefully as it is
more easily abused (Gryczynski et al., 2013). Buprenorphine is a partial agonist with a ceiling
effect that makes it much less prone to abuse. Naloxone can be combined with buprenorphine to
enhance the latter’s opioid-blocking properties, preventing the euphoric effect of further opiate
use and greatly reducing risk of overdose (Debelak et al., 2013). This allows individuals to not
feel withdrawal symptoms or experience the opiate-induced euphoria they strongly desire. When
properly titrated, the net result is that individuals feel physically “normal” or “well.” Mentally,
the intensity of the craving is reduced because they know that the high cannot be felt, which
allows them to proceed with activities of daily life such as employment, maintaining
responsibilities, and engaging in healthy, productive relationships (Dhawan & Chopra, 2013).
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Treatment retention could help increase individuals’ appreciation for this benefit as well as
strengthen their ability to resist the temptation to return to illicit opiate use.
Organization of the Remaining Chapters
Chapter One was a general overview of the context and background of this study.
Chapter Two is a broad examination of the research and theories related to the study
components. Chapter Three details the study methodology as well as the reliability and validity
of the four assessment instruments used to compile data. Chapter Four is a submission of the data
gathered for the study and the study results. Chapter Five summarizes the research data from the
study, presents relevant conclusions from the findings, and offers recommendations for future
research and clinical practice.
Summary
The association of hope, grit, and readiness to change with retention in office-based
buprenorphine programs and quality of recovery was examined in this study. Higher levels of
hope, grit, and readiness to change may be significant predictors of treatment retention and
recovery stability. Identifying these data may be beneficial to treatment planning for individuals
going forward in office-based MAT programs.
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CHAPTER TWO: LITERATURE REVIEW
Previous research indicates that opioid abuse has been a significant problem since the
early 1900s in the United States and continues to be an epidemic around the world (Brown &
Altice, 2014; Larance et al, 2015; Strobbe et al., 2011). The diagnostic features and current
treatment practices for opioid use disorder (OUD) are reviewed in this chapter. Recent research
has indicated that medication-assisted treatment (MAT) can help opioid-addicted individuals
maintain life without the problematic behavior brought on by illicit opioid use (Lobmaier et al.,
2010; Martin & Finlayson, 2015; Rastegar et al., 2016; Unger, 2017). Data and literature on
MAT and the potential for office-based MAT to produce improved recovery outcomes (Brezing
& Bisaga, 2015; Moore et al., 2016) are examined in this chapter. Personal characteristics of
hope, grit, and readiness to change, which may be predictors contributing to successful treatment
results (Marcovitz et al., 2016; Perreault et al., 2015; Tsui et al., 2014) are also reviewed. The
chapter concludes with a discussion of the relevance and importance of researching this topic.
Opioid Use Disorder
OUD can be defined as a problematic pattern of opioid use resulting in significant
impairment and distress at a clinical level (APA, 2013). Addiction can also be viewed as a
chronic but treatable mental condition characterized by dependence and self-destructive behavior
(Pecoraro et al., 2012). DiClemente (2018) defined addiction as an established pattern of
maladaptive behavior where dependence is present with psychological and physiological
dimensions and the individual is very resistant to change.
An opioid is a psychoactive chemical related to and interacting with opioid receptors on
nerve cells in the brain and nervous system designed primarily to relieve pain. Opioids can also
produce pleasurable effects such as increased energy and a sense of well-being, even euphoria
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depending on the amount ingested. These drugs can be used orally or by inhalation, smoking, or
intravenous injection. Opioids are a class of drugs that include the illicit drug heroin as well as
prescription pain relievers such as oxycodone, hydrocodone, codeine, morphine, and fentanyl
(Westreich, 2015).
History of Opiate Use
Medical texts indicate that opium was used in India and China as an analgesic as far back
as the 8th century (Pecoraro et al., 2012), and later throughout all of Europe. Sixteenth-century
references to addiction in Germany, England, and Egypt indicated problematic use and the
inability to discontinue use of the substance. Opium dens became popular in 17th-century China
and continued through the 19th century, spreading into England and later to the United States.
Morphine was already a problem in the United States, following its use as an effective pain
medication on the battlefields of the Civil War. The hypodermic needle was introduced in 1853
(Pecoraro et al., 2012), and injecting the drug became the most efficient delivery method.
Whereas opium was stigmatized and associated as the drug of the poor or minorities,
morphine was accepted as medicinal, and its use became widespread in the United States and
Europe (Pecoraro et al., 2012). As a result, addiction problems became evident across higher
socioeconomic levels. In an attempt to find a pharmacological remedy for opiate dependence,
Bayer Pharmaceuticals developed heroine and marketed it as a nonaddictive cough medicine and
cure for morphine dependence. Ten years later, in the early 1900s, heroin was the most abused
substance in the United States. Between opium, morphine, and heroin, the country had a
significant opioid use problem in the early 20th century. The Harrison Narcotics Act of 1914
outlawed the purchase of nonprescription heroin, and the Heroin Act of 1924 banned any
production or sale of the drug (Pecoraro et al., 2012). Heroin use continued to be a problem
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across all socioeconomic levels, with an estimated 500,000 users in the United States in 1970.
Despite worldwide governmental efforts to curb opioid production and sale, the United Nations
Office on Drugs and Crime estimated in 2007 that opiate users worldwide totaled between
15,000,000 and 20,000,000, with 11,000,000 using heroin (Hedegaard et al., 2017). Although
U.S. heroin use had stabilized to approximately 1,200,000 users, 5,200,000 people reported
abusing prescription opioids. The American Society of Addiction Medicine (ASAM, 2016)
reported that in 2015, approximately 2,000,000 individuals were diagnosed with a substance use
disorder involving prescription pain relievers; over 500,000 of these diagnoses involved heroin.
The Centers for Disease Control and Prevention estimated the total economic burden of
prescription opioid misuse alone in the United States at $78,500,000,000 per year, including the
costs of health care, lost productivity, addiction treatment, and criminal justice involvement as
well as the rising incidence of neonatal abstinence syndrome due to opioid use and misuse during
pregnancy (NIDA, 2018). When factoring in all aspects, including overdose deaths, the total
economic cost approaches $700,000,000,000 per year (NIDA, 2018)
In response to the current opioid crisis, improving access to treatment and recovery
services is one of the U.S. Department of Health and Human Services’ main focuses. This
includes further developing and improving MAT programs and outcomes (NIDA, 2018). While
opioid pain medication prescriptions are increasingly being regulated and reduced, a high
percentage of the opioid-addicted population will convert to heroin based on supply and demand,
so the problem must continue to be aggressively addressed going forward (Martin & Finlayson,
2015). Hedegaard et al. (2017) estimated that up to 80% of American heroin users began their
addiction with prescription pain medication.
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All prescription pain medication use does not lead to heroin addiction. Based on
information from the 2017 National Survey on Drug Use and Health, most people do not misuse
prescription pain medication, although 2,000,000 Americans misused prescription pain relievers
for the first time in 2017 (NIDA, 2018).
Diagnostic Features of Opioid Use Disorder
Opioids are psychoactive chemicals commonly used for pain management (Molfenter et
al., 2015). They are abused at an epidemic rate across the United States in both big cities and
small towns. Opioid abuse affects many other countries as well, including Canada (Socías &
Ahamad, 2016), Europe (Sordo et al., 2017), and China (Lee et al., 2017). OUD can be defined
as a problematic pattern of opioid use resulting in significant impairment and distress at a clinical
level (APA, 2013). Symptomology includes being unable to stop or reduce use; significant time
spent obtaining, using, or recovering from opioid’s effects; failure to fulfill major life role
obligations; persistent or recurrent social or interpersonal problems caused by use; physically
hazardous situations; and continued use despite knowledge of having persistent or recurrent
physical or psychological problems caused or exacerbated by opioids (APA, 2013). Opiate users
are often polysubstance abusers, using other substances such as methamphetamine, alcohol,
cannabis, and benzodiazepines, with the last possibly leading to respiratory distress and failure.
Individuals with OUD are at risk of developing mild to severe depression on a short- or longterm basis. Common medical conditions associated with OUD are HIV, hepatitis C, and infective
endocarditis, especially for intravenous users (Suzuki, 2016). Antisocial personality disorder and
posttraumatic stress disorder are seen more frequently in OUD than in the general population
(Carroll & Weiss, 2017; Meier et al., 2014).
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One of the more prevalent features associated with OUD is the presence of clinically
significant problematic psychological or behavioral changes that developed during or after
opioid use, leading to job loss, damaged relationships, or legal consequences (Levin et al., 2016).
Intoxication is evidenced by pupillary constriction, drowsiness, slurred speech, and impairment
in memory or attention. These symptoms are not attributable to another medical condition or
better explained by another mental disorder. Opioid use can begin at any age. Once OUD
develops, it can continue for years with significant and increasingly negative consequences.
Given the intensity of withdrawal symptoms, OUD can be more difficult to overcome than other
substance disorders (Levin et al., 2016).
Treatment Models
Severe withdrawal symptoms that accompany opiate addiction create a special challenge
for conventional substance abuse treatment models. Many substance use disorder treatment
programs, including 12-step programs and cognitive behavioral therapy-focused treatments, are
abstinence based. MAT is becoming increasingly recognized as an appropriate, if not preferred,
OUD treatment. Abstinence-based OUD treatments often have lower retention rates, particularly
in their early stages (Marcovitz et al., 2016) than medication-assisted programs due to extreme
withdrawal symptoms and cravings. The first 30 days of treatment seem to be the most critical in
MAT as well (Hser et al., 2014).
Abstinence-Based Programs
The primary goal of abstinence-based treatment programs is to completely discontinue
use of abused substance. Many abstinence-based programs are modeled after Alcoholics
Anonymous (AA), a 12-step recovery program founded in 1935. This is a mutual support
abstinence-based fellowship that relies on the foundation of the 12 steps of character reform.
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Narcotics Anonymous (NA), a similar program developed for drug abusers, was founded in
1953. Both programs have global membership, which means an alcoholic or an addict can
usually find a recovery meeting almost anywhere in the world. Online meetings for both are
available, so there is ongoing, readily accessible, and consistent support (Brown & Altice, 2014).
AA and NA are not usually compatible with MAT, and long-standing attitudes insisting
abstinence only and the lack of acceptance of medication-assisted recovery can create
disconnects for MAT patients (Friedmann et al., 2010). As research continues to support MAT,
innovative approaches like these could be increasingly more accepted as hybrid-type therapies in
the abstinence-based community. There will not always be agreement between programs and
professional groups regarding these blended and less strenuous methods. For physicians, there is
a dilemma between accepting polydrug use during treatment as a means to improve retention,
with an obligation to do more good than harm for their patients (Strike et al., 2013). Harm
reduction is a relevant strategy when dealing with OUD, depending on addiction severity
(including length of use, method, and substance) and individual treatment goals. Harm reduction
offers an option for avoiding criminal behavior and safely obtaining substances for addicts with
low motivation and minimal readiness to change (Marchand & Oviedo-Joekes, 2017).
Other abstinence-based programs utilizing cognitive behavioral therapy or any other
treatment approach are not as effective for treating opiate addiction as MAT programs but are
better than placebo or no treatment (Sigmon et al., 2012). While psychosocial therapy has been
proven to be a valuable adjunct (Pecoraro et al., 2012), it is not as effective as a stand-alone
treatment. However, 12-step programs can be an effective supplemental adjunct for MAT of
OUD (Lobmaier et al., 2010).
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Methadone
Methadone is a synthetic opioid used in MAT to help people reduce or stop heroin use or
other illicit opiate use. Methadone was developed in 1937 during World War II in Germany as a
pain reliever and is still sometimes used to treat chronic pain in a variety of settings (Tucker et
al., 2015). Methadone was introduced in the United States in 1947 and has been used to treat
heroin addiction and to prevent and improve withdrawal symptoms since 1965 (Lee et al., 2017).
As an opiate maintenance treatment medication, methadone can be safe and effective when taken
as prescribed and is considered the frontline treatment for severely addicted heroin users
(Maremmani & Gerra, 2010). It is most often prescribed in a treatment clinic setting in a
program that includes psychosocial support and is usually administered to patients on a daily
basis. After a period of progress with proven stability and compliance, individuals can earn takehome doses; even then, patients usually have to come to the clinic a minimum of 4 times a week
(Lobmaier et al., 2010), which can make maintaining steady employment and other normal life
activities more difficult. Any take-home doses are strictly regulated to prevent misuse or
diversion.
Methadone can be effective for increased treatment retention as well as reduced heroin
use and criminal behavior. This treatment approach is a safer way for the individual to get the
substance that produces the desired effect in a controlled and regulated environment, reducing
the probability of participating in risky behavior (Lobmaier et al., 2010). However, more opioids
can be used with methadone to increase the effect, whereas with Suboxone (buprenorphine and
naloxone combined), additional opiate euphoria and effects are blocked and cannot be
experienced.
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Participants in a methadone study conducted by Tucker et al. (2015) expressed several
negative attitudes regarding methadone’s harmful physical effects, including perceived
ineffectiveness in reducing heroin cravings, increased cravings for other drugs, lack of
motivation and economic productivity, and even death. Tucker et al. reported that fatal
methadone overdoses have increased over the years in several demographics across Canada. the
country. These and other negative characteristics such as required frequency of visits to the
prescriber (often on a daily basis, especially for the first few months), methadone’s impairing
effect, and the stigma of “not really being in recovery” are in addition to methadone addiction
(Gryczynski et al., 2013).
Buprenorphine
Buprenorphine is often viewed as a better treatment alternative than methadone
(Gryczynski et al., 2013). Risks of overdose, respiratory distress/failure, and sedation in
methadone treatment are not present with buprenorphine. MAT with buprenorphine derivatives
allows patients to lead normal, productive, and stable lives (Unger, 2017). Several participants in
a study by Sohler et al. (2013) expressed the same idea of being able to lead a normal life and
feeling like themselves when comparing methadone to the benefits of transitioning to
buprenorphine. Former methadone participants typically expressed their choice to switch to
buprenorphine treatment as a decision against methadone. Buprenorphine was perceived as a
helpful medication while methadone was thought to be a harmful narcotic with several difficult
side effects. Positive experiences with nonprescribed buprenorphine were a strong factor leading
these individuals to seek buprenorphine treatment (Sohler et al., 2013)
Buprenorphine has been used to treat opioid dependency since 1996 (Nosyk et al., 2015).
Buprenorphine has both agonist and antagonist properties and is considered a partial agonist. It
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produces the opiate effect of stopping withdrawal symptoms as the dose is increased up to a
certain point. Beyond that point, further dosage increases do not cause any greater activation;
thus producing a ceiling effect. When taking buprenorphine in a properly titrated dose, the
individual does not experience the euphoria of an opiate but does get enough effect to offset
withdrawal symptoms. The individual will not be high, but will not be sick either. Addicts must
develop the desire to change to be greater than the temptation to use. Buprenorphine patients
often try to use in between doctor visits and get back on buprenorphine to pass the next drug
screen. Unscheduled drug screens and pill counts can help deter this behavior (DeMaria &
Risler, 2012).
Naloxone
The Food and Drug Administration approved the fixed dose combination of
buprenorphine and naloxone in 2002 (Unger, 2017). Naloxone is present in this combination to
discourage misuse; it serves no other purpose. Naloxone blocks the effect of opioids, so if an
individual taking the combination uses an opiate, the euphoric effect will not be experienced.
This combination was thought to decrease the potential for diversion and misuse of
buprenorphine because, if injected, the naloxone will cause immediate withdrawal symptoms in
those already physically dependent on other opioids. In a qualitative study on opioid abusers in
New York City, Sohler et al. (2013) included some comments from study participants regarding
beginning use of buprenorphine/naloxone such as “You feel yourself again, you feel normal.
That’s what I’m looking for” (p. 116). Another study participant stated,
Look, it’s offering me a way out without suffering so much, that’s what I’m interested in.
I’m chicken s**t, I don’t want to feel the withdrawals, I don’t want to go through all that,
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and that’s what I’m interested in. And then it can maintain me. So, you know, it’s
definitely beneficial for me. To me it’s like a miracle drug. (p. 116)
A third participant stated,
And I tried suboxone I felt—I felt energetic. I felt like I haven’t ever touched dope. I felt
alive. I felt totally different like my mind was free, wasn’t cloudy, you know. I was
awake. I was energetic. It was like I was a new me. (Sohler et al., 2013, p. 116)
Unger (2017) estimated that approximately 80% of the 2,000,000 people in the United
States who are opioid dependent are not receiving the treatment they need to change and get
well. Unfortunately, uninsured individuals often do not have access to treatment. They are some
programs for those without insurance, and funding for them should increase over the next few
years, including increased access to insurance for those with substance use disorder (Hutchinson
et al., 2014). The treatment pendulum is swinging in a positive direction, but change takes time,
and people are dying every day from opioid overdose, which includes buprenorphine being taken
with benzodiazepines (Lintzeris & Nielsen, 2010). But it is also understood that not every one of
those 2,000,000 people was ready to take action to change.
Office-Based Buprenorphine
The United States is motivated for change, but office-based buprenorphine treatment
continues to be significantly underutilized, primarily due to physician concerns regarding patient
nonadherence (Hutchinson et al., 2014). Primary care physicians are now the largest prescribing
group for buprenorphine products, making the treatment more accessible. There were an
estimated 2,100,000 ambulatory buprenorphine treatment visits in 2013 (Turner et al., 2015).
Primary care physicians and general practitioners can take the 8-hr online course provided by the
ASAM to obtain a U.S. Drug Enforcement Administration waiver for prescribing buprenorphine,
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which will allow them to provide office-based opioid dependency interventions per the Drug
Addiction Treatment Act of 2000 (Unger, 2017). There is some resistance to increasing access to
buprenorphine from primary care physicians, however. Blum et al. (2016) recommend that only
physicians who are certified in addiction medicine or addiction psychiatry should be able to
prescribe to 200 patients and that general practice prescribers should maintain a limit of 100.
This treatment would save lives and money. Every dollar invested in opioid addiction treatment
saves society an estimated seven dollars in drug-related crime and criminal justice costs (Unger,
2017).
Unger (2017) posited that roughly 50% to 80% of opioid-dependent patients remain
opioid free for 12 months while taking buprenorphine. The ability to get the medication on a
weekly or monthly basis allows individuals to live a more normal life as they do not have to visit
the clinic as often.
Research has indicated the necessity of ongoing treatment after opioid cessation
(Westermeyer & McCance-Katz, 2012). Effective treatment for opioid addiction will always
require a combined physiological and psychological approach. Most treatment programs do not
adequately address the neurological and physiological issues of substance dependence
(Dehghani-Arani et al., 2013). Improved treatment retention produces better treatment outcomes.
Studies have shown that noncompliant patients have significantly higher relapse rates than those
who are compliant (Bolek et al., 2016; Dhawan & Chopra, 2013; Griffin et al., 2014). MAT has
a positive influence on illicit heroin use as well as on HIV risk taking and criminal behavior
(Lobmaier et al., 2010). Understanding factors that drive treatment compliance and
noncompliance may assist providers in supporting patient retention and recovery (Tkacz et al.,
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2012). Since improved MAT compliance supports improved abstinence and recovery,
strengthening compliance could lead to decreased relapse rates for MAT.
These three treatment models—abstinence, methadone, and buprenorphine—are
significantly different in concept and delivery and do not overlap well, particularly in the
psychosocial treatment component. Even people who successfully utilize either MAT program
may not blend well with people in an abstinence-based program (often 12-step or religious
based), especially individuals in OUD recovery. Strobbe et al. (2011) identified this phenomenon
in a clinical trial of mixed treatment models. Patients receiving buprenorphine did not have their
own dedicated group for concurrent psychosocial treatment, and significant tension often
surfaced between those in the abstinence-based program and those in the MAT groups.
Gryczynski et al. (2013) found that perceptions of Suboxone as a helpful medication were
growing while methadone was perceived as a harmful narcotic with multiple unwanted physical
effects. Positive experiences with nonprescribed “street buprenorphine” were a central factor in
participants’ decisions to seek buprenorphine treatment (Gryczynski et al., 2013). Despite an
abundance of research indicating that MAT is a safe and effective treatment for opiate addiction,
this treatment approach continues to be ignorantly stigmatized (Kelly et al., 2012), which can
discourage patients from entering treatment (Roose et al., 2012).
Treatment Outcomes
Unfortunately, overdose deaths are a reality in the OUD population. People diagnosed
with OUD who seek traditional abstinence-based substance abuse treatment without medication
often have higher relapse rates than those in MAT, primarily due to withdrawal severity and
postacute cravings (Brown & Altice, 2014). Even individuals in pharmacotherapy treatment can
relapse and die, especially if their tolerance has declined and they attempt to use at pretreatment
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levels. Helping individuals with OUD remain connected in treatment gives them the best chance
to recover (Tsui et al., 2014).
Treatment retention is an important predictor of favorable treatment outcomes (Hser et
al., 2014). Improved treatment retention produces better treatment outcomes (Kampman &
Jarvis, 2015). Studies have shown that noncompliant patients have significantly higher relapse
rates than those who are compliant (Carroll & Weiss, 2017; Gryczynski et al., 2013).
Understanding factors that drive treatment compliance and noncompliance may help providers
better support patient retention and recovery (Tkacz et al., 2012). Since improved MAT
compliance supports improved abstinence and recovery, strengthening compliance could lead to
decreased MAT relapse rates.
In a multisite trial comparing methadone and buprenorphine programs over a 3-year
period that involved over 1,200 participants, Hser et al. (2014) concluded that 25% of the
buprenorphine participants dropped out within the first month of treatment. This finding
suggested that the first month is a critical period and that special efforts are needed to help these
individuals develop resilience and overcome treatment resistance that seems to occur in early
treatment (Hser et al., 2014). Other conclusions from this large study were that methadone
appeared to be associated with better treatment retention for individuals with OUD than
buprenorphine, buprenorphine was associated with lower continued use of illicit opioids, and that
with higher doses of both medications, treatment retention increased proportionately (Hser et al.,
2014).
In a study involving over 700 new buprenorphine patients in a national sample, Tkacz et
al. (2012) found that noncompliant patients who did remain in treatment were more than 10
times more likely to relapse. Being able to identify motivation levels might help determine which
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treatment is most appropriate for each individual. Also, the ability to develop a relapse profile
would help treatment providers to recognize those with lower motivation for treatment and
higher risk for relapse (Tkacz et al., 2012).
Streltzer et al. (2015) conducted an observational study of prescription opioid-dependent
pain patients being treated with buprenorphine. Forty-three patients were monitored for 5 years.
Study findings showed that buprenorphine treatment was effective for these patients and that
most had reduced pain levels with buprenorphine compared to when they were being treated with
other pain medication. They also reported less preoccupation with pain. Streltzer et al. found no
differences in treatment outcomes between patients with a history of substance abuse and those
without a history of substance abuse.
Soyka et al. (2011) found cognitive impairment to be similar in a study comparing
methadone and buprenorphine patients. These patients compared favorably with those receiving
long-term heroin treatment but not as well with healthy controls. The buprenorphine patients
performed better in psychomotor performance under stress conditions than the methadone group.
Marsch et al. (2016) conducted a randomized controlled trial of buprenorphine taper with
opioid-dependent young adults and adolescents. They compared a 56-day taper to a 28-day taper
and found the 56-day group was retained in treatment significantly longer than those in the 28day group. Surprisingly, they found daily attendance requirements to be associated with shorter
retention and decreased abstinence compared to the group that attended two or three times
weekly, and these results were independent of taper duration.
Marcovitz et al., (2016) retrospectively reviewed medical records from 202 patients in
MAT programs using buprenorphine and naloxone from two different facilities to identify
predictors of early dropout. The results showed that more than 1 in 4 patients dropped out of
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treatment. Significant dropout predictors included being 25 years of age and opioid use in the
first month of treatment. Patients with suicide attempt histories were much less likely to
disengage from the program.
Griffin et al. (2015) assessed health-related quality of life for 653 prescription opioiddependent patients and compared test scores with the general population. The sample of OUD
patients reported worse physical and mental quality of life scores than the general population but
similar to other OUD populations. Griffin et al. recommended addressing the assessment needs
of the growing population of individuals who primarily abuse primarily prescription opioid pain
medication. This group is more likely to be treated for chronic pain, not to have hepatitis C, and
never to have used intravenously.
Access to Care
Beginning in 2015, cultural perceptions changed regarding both the level and severity of
prescription pain medication addiction. Heroin is an appropriately stigmatized substance, but
opioids have been accepted as prescription drugs. The percentage of people in the United States
who are addicted to opioid pain medication is at an epidemic level (NIDA, 2018). In 2015,
seven people died every day from a prescription medication overdose (ASAM, 2016). As this
information continues to be publicly circulated, general awareness is improving, leading to
increased resources being committed to opioid treatment nationwide.
People without health insurance are often unable to access adequate treatment services to
overcome their addictions. Even those who are insured but have higher copays and deductibles
have limited access to treatment (Abraham et al., 2017). Unfortunately, in the current U.S. health
care structure, insurance, not necessity, greatly dictates treatment. The uninsured or underinsured
often have to rely on less effective community care treatments. Fortunately, national health care
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monies are being allocated to help individuals who would not otherwise be able to enter
treatment, and MAT is gaining momentum as a treatment for these individuals (Abraham et al.,
2017).
Individual Characteristics
Identifying how motivation to change relates to positive outcomes is important for
understanding how treatment for alcohol abuse or other behavioral problems can work.
Maremmani and Gerra (2010) indicated that additional behavioral research is needed to evaluate
treatment outcomes of particular subgroups and individual characteristics. Cadet (2016) posited
that substance use disorder treatment should include an element of resilience enhancement,
particularly for higher risk individuals. The pretreatment stage of change has been identified as
an important predictor of outcomes for a wide range of disorders. Pretreatment motivation also
strongly predicts both treatment retention and recovery quality during treatment (DiClemente et
al., 2004). Motivation is a well-established predictor of recovery for addictive behaviors.
DiClemente et al. (2017) found no research that addressed motivation and OUD treatment and
identified two studies that incorporated brief motivational interventions into current opioid
treatment. Higher levels of personal motivation defined as grit and hope could prove to be
indicators of successful treatment outcomes.
Hope
Snyder et al. (1991) defined hope as a cognitive set comprising a derived sense of
successful agency (goal-directed determination) and pathways (planning of ways to meet goals).
In a family addiction intervention setting, being prepared for change at initial assessment
predicted higher hope and coping skills after intervention for the addicted family member
(Bradshaw et al., 2015). Initial levels of hope also predicted family coping skills following the
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family member’s treatment. Research has indicated that hope can be a positive indicator of
quality outcomes in mental health treatment. Arnau et al. (2007) found higher levels of hope
agency to predict reduced anxiety and depression scores over a 1-month span. In a longitudinal
study of 45 mutual-help recovery home residents, Dekhtyar et al. (2012) also found hope agency
to be a significant predictor of positive treatment outcomes and lower reincarceration rates.
Lower hope pathways scores were not predictive in that particular study. In a longitudinal
sample of men and women in substance abuse recovery who lived in sober living homes, higher
hope agency was again predictive of lower anxiety and depression levels (May et al., 2015).
When recovery can be seen as a process, a journey that includes hope where individual
goals are defined and pursued regardless of symptoms or stigmas, then hope can grow and
contribute to a stronger and more optimistic recovery (Corrigan et al., 2017). Hope provides
energy and perspective to the recovery process. Treatment models are often viewed as a goal of
abstinence, and all else is failure. Addicts with failed attempts to get sober may feel further
devalued in this process. Individual hope can be cultivated and multiplied to be drawn from
when difficult struggles arise, such as cravings or triggers for the addict.
Hopelessness is a defining characteristic of addiction, as behavior that was once just a
habit without significant consequences and thought of as fun is now a consuming desire that
cannot be controlled (Bradshaw et al., 2015). Self-regulation is gone from an activity that was
once manageable. The individual struggles to make sense of the change, trying desperately to
return to the former level of use, but to no avail. The feeling of hopelessness tells the addict that
change is not possible and a return to the healthy self will never happen. Frustration and fear
drive the individual to continue in the maladaptive behavior, as loss continues to dominate.
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Having hope brings an organic change at the core of one’s self (Snyder, 2002). Hope
creates momentum and motivation and positive energy to begin to restore the loss and replace it
with achievement and gain. The addict can be empowered with hope to make amends, return to
employment or school, and repair valuable relationships that were destroyed with the lies of
addictive behavior. Hope allows addicts to see that change is possible, that they just might be
able to return to sanity and become the person they really want to be and not live incongruently
between actual behavior and desired behavior. Certainly, a goal-oriented mindset, including selfefficacy and hope, could be a productive and key component in the addiction recovery process
(May et al., 2015).
Grit
Grit can be defined as perseverance and passion for achieving long-term goals
(Duckworth et al., 2007). Debelak et al. (2013) described grit as a higher level operational
construct comprising perseverance of effort and consistency of interest toward accomplishing
goals and achieving success. Grit does not depend on intelligence, IQ, or talent, but is the
sustained and focused application of talent over time to achieve a goal in spite of setbacks or
obstacles (Duckworth et al., 2007). Duckworth et al. (2007), in two separate studies, evaluated
over 2,500 first-year West Point cadets and found that higher grit scores were predictive of
success in the grueling first-year program. Grit scores were more accurate in predicting which
cadets would endure the challenge and which ones would give up and quit than the whole
candidate score, which is a weighted combination of SAT scores, high school ranking, physical
fitness, and leadership ability. Furthermore, grit was a stronger predictor of graduation than
conscientiousness toward studies, caring about the school, or having a feeling of safety
(Duckworth, 2016). The importance of intellectual talent in achievement in all professional
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domains is well established, but less is known about other individual differences that can predict
success. Grit demonstrated incremental predictive validity of success measures over and beyond
IQ and conscientiousness in the West Point study as well as in two other academic achievement
measures (Duckworth et al., 2007).
Perseverance and sustained focus are two key elements in successful addiction recovery
(Cook et al., 2015). Addiction recovery is about strengthening the ability to resist fear and
temptation while continuing to pursue the goals and success of sustained sobriety. Recovery is an
undertaking that requires significant willpower to resist strong temptations to quit or give in.
Griffin et al. (2016) posited that developing interventions to improve grittiness could be useful
for some individuals in certain contexts with specific deficits levels. Surprisingly, reward
processing, self-control, and impulsivity are not consistent predictors of successful addiction
treatment outcomes (Griffin et al., 2016). Marcovitz et al. (2016) identified early opioid use as a
predictor of treatment dropout. Commitment to persevere toward treatment goals could
strengthen resistance to temptation. An individual’s grittiness level could be a predictor of
success in substance use disorder treatment outcomes.
Stages of Change
Evaluate an individual’s readiness for change is one of the best ways to measure
motivation for treatment. Connors et al.’s (2013) updated stages of change model is designed to
assist clinicians in this process so that accurate assessment and appropriate treatment
recommendations can be made. This model was designed to represent the typical process that
can be followed and changing addiction behavior (DiClemente, 2003). Understanding an
individual’s current motivation to change can lead to more accurate treatment strategies, thereby
improving probability of a successful treatment outcome. Also, helping clients to understand
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where they are in the stages of change process helps them to know and better understand what
they must do going forward in setting and achieving treatment goals.
This transtheoretical model comprises five basic stages of change readiness. The
precontemplation stage indicates that the individual has a low awareness for the need to change,
while the contemplation stage reflects an awareness of the need to change without yet making a
decision to take action. In the preparation stage there is planning and commitment to change,
leading into the action stage of implementation of the strategies and revision as necessary
(DiClemente et al., 2004). The maintenance stage is the process of converting behavior and
integrating the new behavior into a lifestyle. It is important to recognize that even though this is a
linear model where one step progresses to the next, people often regress to previous stages,
especially in addiction (Connors et al., 2013). Although much stages of change research was
initially conducted with smoking and tobacco cessation and later alcohol abuse, these categories
and attributes appear to translate appropriately for other drugs of abuse (DiClemente, 2003).
Precontemplation
Individuals in this first stage of change have the mindset that no change is really needed
and that the issue is not really a problem. They may lack awareness of the severity of the
situation or the reality of the maladaptive behavior (Connors et al., 2013). These individuals may
be defensive, feeling pressured by significant others to seek treatment or have an honest selfassessment of the current situation. They may be resistant to engaging in any evaluation or
activity that may change their perception of the current situation as well as avoiding steps to
change such as rejecting offers for evaluation or treatment. They are not convinced that the
benefits of not using a substance are greater than the consequences of continued use (DiClemente
et al., 2004). They may categorize their use as normal, in spite of negative outcomes or results,
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and may acknowledge no need for change, reflecting a mindset of denial. However, some
individuals in the precontemplation stage do still seek treatment, often to satisfy others or to
avoid significant negative consequences such as jail or divorce. The individuals are usually in
denial of how their addiction affects everyone involved.
Goals for this population could be honest self-assessment or self-reevaluation,
environmental reassessment, and raising awareness and consciousness of the reality of the
current situation (Connors et al., 2013). Projecting future outcomes with continued current
behavior (e.g., “Where do you see this going in 6 months?”) could help force change-resistant
individuals to an honest self-assessment and allow for transition to the next stage of change.
Contemplation
The contemplation stage’s basic goals include compiling decisional information and
considerations, examining these data, and engaging the comparative process to resolve decisional
conflict, which is necessary to successfully transition into the preparation stage (DiClemente,
2003). Individuals in the contemplation stage have begun to consider making a change in
behavior but have not yet committed to taking action to effect the change. The current
maladaptive behavior may be critically evaluated more frequently, with the individual
acknowledging the consequences and being more receptive to honest self-assessment of the
current behavior. In this stage, the individual recognizes that a problem exists and is often trying
to devise a way to continue the behavior while minimizing the consequences. Individuals may
enter treatment but still be in the contemplation stage and not necessarily the action stage, as they
may be evaluating the extended range of the treatment process without actually committing to
sustained change.
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DiClemente et al.’s (1991) smoking cessation study categorized individuals in the
contemplation stage as those who did not quit for more than a day over the past year and who did
not expect to quit during the next month but had tried to quit in the past 30 days. Although they
were considering behavior change and seeking treatment, their Action scale scores were below
average. The contemplation stage is not always the launchpad into the preparation stage and then
action (Connors et al., 2013). Moving forward is the goal, but some people can remain in this
stage for longer periods of time, and some shift back to precontemplation, losing motivation to
change. Once this decisional conflict is resolved, the individual can progress to the preparation
stage.
Preparation
The preparation stage involves primarily strengthening the commitment to change and
making an action plan to accomplish the goal of changed behavior. In this stage, the individual
has developed an intention and a readiness to change in both behavior and attitude and is on the
verge of taking action. Some level of change may have already occurred in some areas; for
example, reducing time and/or money spent toward the behavior. These individuals may have a
higher level of confidence in their ability to be successful in treatment. Those in the preparation
stage rate the positives of the behavior lower and the negatives of the behavior higher than those
in the two previous stages (Connors et al., 2013). A sense of purpose and ownership of the
recovery plan is developed, further enhancing motivation to action. The feeling of self-liberation
that can begin in this stage is also highly motivating.
There are peripheral issues that often must be addressed in this transitional stage such as
dual diagnosis mental disorder, family obligations, legal situations or employment
responsibilities, and other substance use (Rogers et al., 2019). Some may need to remove
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themselves from toxic individuals or situations that would hinder taking action toward change.
The environments of people in the preparation stage should be thoroughly evaluated in order to
identify stumbling blocks to recovery (DiClemente et al., 2017). All of these components should
be included in the action plan developed during this stage. A well thought out plan anticipates
potential threats to taking and maintaining action identified and addressed in the preparation
stage. Psychotherapy may help these individuals deal with feelings and emotions that may
unexpectedly arise during the change process.
Action
The four main components of the action stage of changing addictive behaviors are (a)
gaining freedom from the old behavior by engaging change processes and the strategies of the
action plan, (b) developing a significant level of commitment, (c) being able to revise the action
plan and make adjustments as needed, and (d) managing temptations and cravings that could lead
to relapse, which would interrupt the process of developing new behavior (DiClemente et al.,
2003). A relapse could possibly cause individuals to regress back to the precontemplative stage,
and it could take an extended period of time—even years—for the individual to regain
motivation and build back to the action stage of behavior change and recovery. Therefore,
relapse prevention is a major component of the action stage. Relapse prevention and recovery
growth are primary elements of the maintenance phase, but they are also critical in the action
stage. A period of abstinence is necessary in order to reestablish self-regulatory control, which is
lost in addiction (Connors et al., 2013). Once the addiction develops to a certain level, the
individual loses the ability to control the problematic behavior, which allows for strengthening
the maladaptive habits and the related thought patterns. Regaining self-regulation can be a very
difficult process, as the individual has to redevelop the ability to resist engaging in the old
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behavior, no matter the situation. Depending on the severity of the condition, this may only be
accomplished in an inpatient or detoxification setting at the beginning of treatment. Behavior
reinforcement and counterconditioning are necessary elements for early treatment as well
(Connors et al., 2013).
The action phase is the time when individuals who are committed to making a change
begin to disconnect from the social element (people, places, and things) of the old behavior, and
resist the physical cravings and mental temptations of the addiction (Connors et al., 2013). This
may include involving a physician to use medication if appropriate. Medication can be a key
component in allowing the individual to avoid the severe physical cravings and withdrawal
symptoms of opioid use. The medication can also reduce the severity and intensity of the
psychological temptations. Also, a physical exercise program recommended by the physician
could be helpful because motion can change emotion. Individuals who have advanced to the
action stage and many individuals in successful addiction recovery have reported that
incorporating exercise into the action plan for change was very beneficial, as the pursuit of wellbeing and health seemed to replace the feeling of getting high and offset the reduced social circle
(DiClemente, 2003).
Some action may be temporary on purpose, such as a pregnant woman stopping smoking
only for the term of the pregnancy or someone not using drugs while on probation with the court.
While this may seem counterproductive, this temporary change in behavior allows the individual
to experience some of the benefits of abstinence, even though the plan is to return to the old
behavior. The client’s attitude may shift in acknowledging the benefits of recovery, even
unintentionally, which can be helpful in future attempts to change, allowing for a potentially
quicker path to the action stage.
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Maintenance
Strengthening relapse prevention skills is a key goal for individuals entering into the
maintenance stage of change (Connors et al., 2013). As abstinence from the maladaptive
behavior is maintained, the client is better able to maintain and build on gains that have been
realized in treatment or the action stage. At this point, the individual is incorporating the new
behavior pattern into an extended lifestyle, making the new behavior the new normal. Individuals
in the maintenance phase must continue to be mindful of relapse’s consequences, being careful
not to operate in a false sense of security or forgetting the severity of the difficulty that the old
behavior caused. Complacency can be the enemy of recovery. Loneliness can also be a factor to
address in maintenance. A complete shift in an individual’s social life can be a difficult process,
as many of the previous social connections that were healthy have been damaged or broken.
Many addicts relapse during this time of social change because when the negative friends and
acquaintances are removed, old friends who were lost because they did not participate in the
maladaptive behavior may not wish to reconnect until change is evident. This leaves the
individual seeking change feeling lonely as the social connections are usually not quickly
replaced, and loneliness can lead to relapse.
Unfortunately, relapse is common with addiction recovery (DiClemente, 2003). Whether
it is a one-time slip or an extended relapse, some momentum is lost. Abstinence-based treatment
and recovery are more apt to regard a one- or two-time use as a catastrophic event, and recovery
starts back at Step 1. Behavioral theories tend to be a bit more lenient, viewing a slipup as an
opportunity to learn and grow stronger in recovery (DiClemente et al., 2017). There are
differences between a slipup and a full-blown relapse, depending on how long and deeply the
individual reengages in the problematic behavior (DiClemente, 2003). The longer the relapse, the
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further back the individual may regress in the stages of change. Addiction is considered a
progressive disease; a relapse can take the individual deeper into the addiction than before,
possibly resorting to new actions to get more of the desired substance.
Recycling is the term used to describe a relapsed individual going back to earlier stages
of change in order to resume recovery action (DiClemente, 2003). Relapse can be particularly
discouraging in the maintenance stage, but understanding the concept of recycling can help the
relapsed individual to not lose all hope and not completely give up and quit. Relapse rates for
opiate users can be worse than those of other substance users, given the severity of the physical
withdrawal symptoms, so understanding and including the principle of recycling in OUD
treatment can help keep individuals connected to treatment even after relapse. Individuals who
are successful in long-term recovery seem to be able to minimize lapses or slipups and avoid
full-blown relapse, which is a return to dependence (McDonough, 2015).
Recognizing and understanding the individual characteristics of motivation for treatment
success will allow providers to make focused and specialized efforts to improve resilience and
treatment outcomes (Ahmadi & Jahromi, 2017). Understanding the stages of change and
identifying the client’s current position in this model can be beneficial in developing an
individualized plan for the particular client. External motivations (probation, job loss, divorce,
financial loss) and internal motivations (self-image, guilt, shame, stress, depression) are factors
in treatment retention and successful outcomes. Chronic pain is also a significant factor to
overcome with the OUD population (Oberleitner et al., 2019).
Individual personality characteristics and attitudes such as grit and hope may also be
predictors of the ability to remain abstinent and engaged in recovery as these qualities can reflect
motivation, and motivation is a well-established predictor of recovery for addictive behaviors
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(DiClemente et al., 2017). Marchand and Oviedo-Joekes (2017) noted that patient-centered
approaches would help to identify each client’s unique values, preferences, and needs, which is
important to improve treatment retention and successful outcomes. Research has indicated that
better and more frequent assessment and measurement may improve understanding of the
components of readiness to change and motivation as well as how they translate into successful
addiction treatment (DiClemente et al., 2004). The intention in the present study was to identify
and quantify personal characteristics that may help predict treatment outcomes for individuals
entering into an office-based opioid maintenance therapy program.
Summary
A review of the literature showed several points relevant to this study. Opioid abuse has
been a problem worldwide for centuries and has been an issue in the United States since the Civil
War (Pecoraro et al., 2012). Additionally, prescription pain medication abuse has increased
dramatically over the last 20 years (ASAM, 2016), compounding this national dilemma to
epidemic proportion. Opioid-related overdose death rates continue to increase in all age groups
and across all socioeconomic demographics (Hedegaard et al., 2017; NIDA, 2018). Research has
indicated that this condition could continue to worsen (Unger, 2017).
With more restrictive and accountable opioid pain medication prescribing practices being
implemented, the need for OUD treatment will inversely increase, providing individuals with this
disorder an alternative to transitioning to heroin or other illicit substances. Research has strongly
indicated that MAT is one of the better methods for effectively treating OUD (Turner et al.,
2015; Wilson & Fagan, 2017).
Treatment retention has been strongly associated with positive recovery outcomes
(Suzuki et al., 2015; Weiss et al., 2011), and understanding the predictors associated with better
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retention could help direct treatment strategies (Griffin et al., 2015). Precisely targeted strategies
could help providers address the diverse needs of substance abusers and treatment seekers,
support more proactive interventions, create a concentration on motivational enhancement, and
helps researchers understand the larger process of change where addict and treatment provider
meet.
Motivation is a well-established predictor of treatment retention (Cook et al., 2015) and
recovery from addictive behaviors (DiClemente et al., 2017), so being able to measure
pretreatment motivation as represented by the traits of grit, hope, and readiness to change may
result in more accurate treatment planning, possibly leading to more effective strategies and
better treatment outcomes. This study’s focus was on measuring these indicators and treatment
outcomes with individuals participating in an office-based opioid maintenance therapy program.
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CHAPTER THREE: METHOD
The purpose of this study was to examine the relationship between personal
characteristics of hope, grit, and readiness to change with the efficacy of medication-assisted
treatment (MAT) for opioid use disorder (OUD) delivered in an office-based buprenorphine
program. Participants entering the program during the study completed the Adult Hope Scale
(AHS; Snyder et al. 1991), the stages of Change Readiness and Treatment Eagerness Scale
(SOCRATES): Drug Version 7D (Miller & Tonigan, 1996), and 12-Item Grit Scale (Duckworth
et al., 2007) to quantify these three personal characteristics. Each participant was evaluated after
60 days for treatment retention and recovery quality. Recovery quality was assessed using the
Substance Abuse Recovery Evaluator (SURE; Neale et al., 2016). Participant demographics were
detailed, and descriptive statistics were detailed and separated into groups.
Correlations were completed for the participants who remained in treatment for 60 days
to determine the relationship between hope agency, hope pathways, grit, and readiness to change
with recovery quality. Simultaneous multiple regressions were used to determine how much of
the variance in recovery quality could be explained by the three predictor variables of hope
agency, hope pathway, and grit. Readiness scores were eliminated from this regression equation
as the existing clients were 60 days into treatment and did not have readiness scores. Another
regression was conducted for only new clients; this regression included all four variables to
examine the effect of readiness score on recovery quality in this smaller group. A logistic
regression was used to investigate how well each of the four independent variables of hope
agency, hope pathway, grit, and readiness to change could predict the dichotomous dependent
variable of treatment retention for 60 days.
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Research Design
The predictive usefulness of the four personal characteristics of hope agency, hope
pathways, grit, and readiness to change with outcome variables of treatment retention and quality
of recovery after 60 days in an office-based buprenorphine treatment program was examined in
this study. Multiple linear regression models and a logistic regression model were used with the
four predictor variables to determine their relationship with the two dependent variables of
recovery quality and treatment retention.
Participants were assessed at treatment entrance to measure the three internal factors of
readiness to change, grit, and hope. After 2 months in treatment, participants were evaluated for
treatment retention and quality of recovery. Data gathered from these participants at these two
points were used to test each predictive variable. Additional data on hope, grit, and quality of
recovery were gathered from existing clients who had been retained in treatment over 60 days at
the beginning of the study to supplement the power of the research.
Variables
Independent Variable
The predictive value of the four three internal factors of hope agency, hope pathways,
grit, and readiness to change on treatment retention and quality of recovery in the first 60 days in
an office-based buprenorphine treatment program was examined in this study. The four
independent variables for the two hypotheses were the scores on the hope (agency and
pathways), grit, and readiness to change measures. Baseline assessment scores for these four
personal characteristic measures were established at treatment entrance.
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Dependent Variables
The dependent variables for this study were treatment retention and quality of recovery
scores, both of which were measured after 60 days of treatment. The individuals who did not
remain in treatment did not have quality of recovery scores.
Selection of Participants
Participants were adult men and women of various ages, ethnicities, socioeconomic
statuses, and treatment/recovery histories from an office-based outpatient buprenorphine
program. All potential participants met DSM-5 criteria for OUD, moderate to severe (American
Psychiatric Association, 2013), and those willing to participate enrolled in the study at the
beginning of treatment. Exclusionary criteria for participants included active psychosis or an
untreated psychotic disorder, under age 18 years, or pending legal action that might result in
incarceration during the term of the study. All participants signed an informed consent form,
including release of information approval (see Appendix A) for obtaining the appropriate data.
Instrumentation
A standardized intake format developed for the present study was used to gather
participant background and demographic information during intake and clinical interviews.
Hope, grit, and readiness to change scores were measured at treatment outset for new clients and
at the next session for existing clients. Recovery quality and treatment retention were assessed
after 60 days.
Measurements
The rationale for using these three measurements was that hope agency, hope pathways,
grit, and readiness to change seem to be predictive factors in positive outcomes in substance
abuse and other mental health treatment efforts (see Stein et al., 2015).
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Adult Hope Scale
The AHS; Snyder et al., 1991; see Appendix B) measures the participant’s level of hope
for the future. This scale is divided into two subscales: Agency and Pathways. Agency is goaldirected energy, and the Pathways scale measures planning to accomplish goals. This 12-item
measure uses an 8-point Likert-type scale ranging from Definitely False to Definitely True. Four
items measure agency, four measure pathways, and the other four are fillers/nonindicators. The
four agency items identify an individual’s general sense of successful determination related to
goals, with one item reflecting the future, two for the present, and one item reflecting the past.
The four pathways items are related to an individual’s cognitive assessment of the capacity to
create solutions for overcoming obstacles to achieve a goal. This is a pencil and paper exam that
takes most people less than 5 min to complete. Higher scores represent higher levels of confident
expectations to pursue and achieve goals. In this context, hope is not merely optimism or
wishfulness but also a construct including a focus on success, an analytic perspective of a good
probability of goal attainment, and an overall realistic expectation of a positive outcome.
Snyder et al. (1991) examined the reliability of the AHS with six separate samples of
University of Kansas undergraduate students and two samples of individuals in psychological
treatment. The scale’s internal consistency was acceptable, as the coefficient alphas ranged from
.74 to .84 for the entire instrument, with the Agency subscale .from 71 to .76 and the Pathways
subscale from .63 to .80. The test–retest scores were .85 at 3-week interval, .73 over an 8-week
interval, and .76 and .82 in two separate 10-week interval samples, indicating the stability,
reliability and reproducibility of the test scores. A subsequent study (Snyder et al., 1991)
examined the scale’s validity with 241 University of Kansas introductory psychology students, in
which the AHS correlated moderately with several other hope scales. These results were
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replicated in two additional studies (Snyder et al., 1991). Also, Bailey et al. (2007) found the
AHS to be a better predictor of life satisfaction compared to Life Orientation Test-Revised in
two separate studies (N = 331 and N = 215).
Grit Scale
The 12-item Grit Scale (Duckworth et al., 2007; see Appendix C) was developed to
measure the construct of grit, or perseverance and passion. This 12-item measure uses a 5-point
Likert-type scale ranging from Very Much Like Me to Not Like Me at All. Six items measure
Consistency of Interest, and six measure Perseverance of Effort, and the two subscales correlate
at r = .45. This is a pencil and paper exam that takes most people less than 5 min to complete.
Higher scores represent higher levels of passion and perseverance to achieve a desired goal. One
of the motivations for developing this scale was to examine whether or not grit may be as
essential as IQ in higher achievement. Duckworth posited that grit, more than self-control or
conscientiousness, may set apart exceptional individuals who make maximal use of their abilities
(talent + effort = maximum achievement).
The Grit Scale was validated across six studies indicating the stability, reliability and
reproducibility of the test results (Duckworth et al., 2007). The first study involved gathering
data from a large sample of adults to assess the predictive validity of grit with higher levels of
lifetime schooling, while the second study used a similar sample of adults but controlled for
personality traits (Big Five) of openness, conscientiousness, extraversion, agreeableness, and
neuroticism. With the association between grit and educational achievement established, Study 3
examined the association between grit and grade point average (GPA) in 139 undergraduates at
an elite university. Higher grit scores indicated higher GPAs but lower SAT scores, indicating
that less intelligent students compensated for their shortcomings by determination and working
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harder. In Study 4, grit was expected to predict retention in a rigorous summer program and GPA
and military performance scores 1 year later for over 1,200 West Point cadets. Grit predicted
program retention better than any other predictor. However, grit was not the best predictor of
cumulative first-year academic GPAs and military performance scores among cadets who
remained at West Point. In that particular sample, the scale had a reliability coefficient of .79.
Study 5 replicated and extended Study 4, and grit was found to be a predictor of program
retention, whereas Conscientiousness and Whole Candidate scores were not. Study 6 included
175 finalists from the 2005 National Spelling Bee. Results indicated that the students with higher
grit scores worked longer and harder than lower scoring peers, leading the grittier students to
better performance. The Grit Scale had an internal reliability coefficient of .80 in this study.
The Grit Scale demonstrated high internal consistency with a coefficient alpha of .85 for
the overall scale. Subscale alphas were .84 for Consistency of Interests and .78 for Perseverance
of Effort (Duckworth, 2007). Neither factor was more consistently predictive of outcomes than
the other in later analyses, and the two together were more predictive than either one alone.
These findings indicate that both the individual sections and the scale as a whole are internally
consistent.
Stages of Change Readiness and Treatment Eagerness Scale
The SOCRATES: Drug Version 7D (Miller & Tonigan, 1996; see Appendix D) is a 40item instrument with Likert-type 5-point scales from 5 (strongly agree) to 1 (strongly disagree)
used to categorize an individual’s readiness to change into one of five defined stages: These
stages are precontemplative (P), contemplative (C), preparation (D), action, (A) and maintenance
(M). This transtheoretical model comprises five basic stages of change readiness. The
precontemplation stage indicates that the individual has a low awareness for the need to change,
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while the contemplation stage reflects an awareness of the need to change without yet making a
decision to take action. In the preparation stage, there is planning and commitment to change,
leading into the action stage of implementing the strategies and revision as necessary
(DiClemente et al., 2004). The maintenance stage is the process of converting behavior and
integrating the new behavior into a lifestyle. It is important to recognize that even though this is a
linear model where one step progresses to the next, people often regress to previous stages,
especially in addiction (Connors et al., 2013). Although much of the stages of change research
was initially conducted with smoking and tobacco cessation and later alcohol abuse, these
categories and attributes appear to translate appropriately for other drugs of abuse (DiClemente,
2003).
Miller initially developed SOCRATES in 1987 to be a parallel instrument with the
University of Rhode Island Change Assessment by DiClemente and Hughes (1990) to measure
stages of change. SOCRATES was found to be reliable when administered to 1,726 individuals
in the Project Match, which was a multisite clinical trial of psychosocial alcohol abuse treatment,
as well as in a test–retest study. Cronbach’s alpha coefficients of internal consistency were
computed for the entire scale (.72) and for the four subscales (P = .84, C = .67, D = .90, and A =
.89). Maintenance (M) stage items were not included in the original version because it was
intended for use with clients initially presenting for treatment, but this omission was later
corrected in the interest of including all stages. Shorter forms were developed, but scales were
modified to only three in the 20-item version 5.0. The 40-item questionnaire was used in the
present study as it best reflects Connors et al.’s (2013) five stages of change.

55
Substance Use Recovery Evaluator
Treatment retention was measured by the participant being actively engaged in the
program after 60 days. Individuals not remaining in treatment were not assessed for quality of
recovery. The SURE (Neale et al., 2016; see Appendix E) was used to measure quality of
recovery in more detailed terms than just abstinence. The SURE is a 21-item questionnaire of
recovery statements that individuals answer by looking back on the past week. These statements
are rated all the time, most of the time, a fair amount of time, a little of the time, or none of the
time. Three substance use statements are rated never, 1–2 days, 3–4 days, 5–6 days, or every day.
The instrument is divided into five subscales of Substance Use (six items), Material Resources
(three items) Outlook on Life (three items), Self-Care (five items), and Relationships (four
items). A 5-point scoring scale (0–4) is used, with higher scores indicate stronger recovery
overall and in each domain. This is a pencil and paper questionnaire that takes most people 5–15
min to complete.
Neale et al. (2016) developed a 30-item beta measure that was administered to 575
individuals receiving addiction treatment services. With item refinement and a full assessment of
psychometric properties, the 21-item measure was found to be reliable and valid. The alpha
coefficient was .92 for the entire instrument, indicating high internal consistency, and test–retest
reliability was acceptable since there were no significant mean differences between scales and
total score. The five scales correlated positively with similar subscale scores from other
instruments, indicating convergent validity. SURE is a stable, reliable, and reproducible
instrument that can be used as a stand-alone tool or alongside other patient-reported outcome
measures (Neale et al., 2016).
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Research Procedures
Approval for this study was granted by Liberty University’s Institutional Review Board
(see Appendix F) according to the following procedures. Participants were recruited by letter
(see Appendix G), and informed consent (see Appendix A) was discussed with each participant.
A signed consent form initiated data collection. Each participant was assigned a number that was
used throughout the study to protect anonymity and confidentiality. Birthdate was used as a
second identification method. The data from the three pretest and two posttest measures were
entered into an Excel spreadsheet created for this purpose. Records were checked randomly to
ensure accuracy.
Ethical considerations for this study were addressed. This study did not require
withholding or delaying treatment for any participant. Confidentiality of information was
discussed with each participant, with study contact information provided to all participants in
case further information or clarification was needed later. Assessment scores were not shared
with any outside party not relevant to this study. All data were stored securely on passwordprotected computers, with paper records stored behind two locks (door and file cabinet), as
required by the U.S. Department of Health and Human Services. All related flash drives are
stored in a locked file cabinet.
Research Questions and Hypotheses
The following research questions and hypotheses were addressed in this study.
RQ1: Can hope agency, hope pathways, grit, and readiness to change scores predict
recovery quality scores?
H10: Hope agency, hope pathways, grit, and readiness to change scores are not
predictive of recovery quality scores.
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H1a: Hope agency, hope pathways, grit, and readiness to change scores are
predictive of recovery quality scores.
RQ2: Can hope agency, hope pathways, grit, and readiness to change scores predict
treatment retention?
H20: Hope agency, hope pathways, grit, and readiness to change scores are not predictive
of treatment retention.
H2a: Hope agency, hope pathways, grit, and readiness to change scores are predictive of
treatment retention.
Data Processing and Analysis
Data were coded and downloaded into SPSS Version 24, where it was screened, and
missing data were excluded from the analysis. Incomplete survey responses were excluded
before preliminary data screening was conducted to determine if scores on the measures were
normally distributed and if any outliers were present. A correlation, simultaneous multiple
regressions, and a logistic regression were used to determine the predictive strength of the four
independent variables with the two dependent variables.
Role of the Researcher
The researcher conducting this study has worked as a substance abuse/mental health
counselor for 10 years and has been associated with office-based MAT for 4 years. This
experience with literally hundreds of clients and four different programs provided the researcher
with a unique inside perspective to see when MAT works well and when it is not effective. The
researcher’s roles in this study were that of a counselor, a program director, and a researcher
gathering data that may be helpful for future MAT clients and programs.
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Summary
The present study was designed to evaluate the effect of personal internal motivational
characteristics of hope agency, hope pathways, grit, and readiness to change on treatment
retention and recovery quality for individuals participating in an office-based buprenorphine
program. Given the current level of nationwide attention on treatment and solutions for OUD and
prescription medication abuse, data gathered in this study were relevant and beneficial to the
field.
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CHAPTER FOUR: RESULTS
The purpose of this study was to measure the effect of the personal characteristics of
hope agency, hope pathways, grit, and readiness to change on each participant’s quality of
recovery from opioid use disorder (OUD) and treatment retention in an office-based
buprenorphine program. Hope agency, hope pathways, grit, and readiness to change were
measured at treatment outset, and retention and recovery quality were measured after 60 days.
Data were also gathered from existing clients who remained in treatment over 60 days at the time
of study to measure hope agency, hope pathways, grit, and recovery quality. A model that
asserted two hypotheses regarding the relationship between these variables was used in this
study. The first overall study hypothesis stated that hope agency, hope pathways, grit, and
readiness to change scores would be predictive of recovery scores; the second hypothesis stated
that hope agency, hope pathways, grit, and readiness to change scores would be predictive of
treatment retention.
The study goal was to involve a minimum of 50 participants. However, just after
initiation of data collection, one of the programs closed the office that was expected to grow and
provide additional clients for this study. This resulted in a smaller sample size than expected. A
total of 31 adults who met the criteria for OUD and were participating in an office-based
buprenorphine program agreed to the informed consent and completed the recruitment
questionnaires to determine eligibility to participate in the survey. Of them, 16 were new
enrollments to the program, and 15 were existing clients who had successfully participated in the
program for over 60 days at the start of the study. The data analysis process used to examine
whether the data supported the hypotheses is described in this chapter. Study findings are also
summarized.
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Data Screening
A sample of 31 participants was obtained and data were collected from September 19,
2019 to December 31, 2019. The participants were categorized as new or existing clients, and the
appropriate assessments were provided. All responses were believed to be correct as information
was gathered in session with a counselor. When scoring the responses to each instrument, the
data were inspected to identify the cases in which participants selected the same response for
eight or more consecutive items on any of the scales. This never occurred, so all client scores
were retained.
For each client, hope scores were calculated on the Adult Hope Scale (AHS) and
recorded for two subscales, Agency and Pathways. Grit scores were recorded. Readiness to
change scores were calculated for five subscales, Precontemplation, Contemplation, Preparation,
Action, and Maintenance, and the highest score was used as the client’s readiness to change
score, coded 1–5. Existing clients did not have readiness to change scores as they were already in
action and maintenance. Quality of recovery scores were recorded for existing clients and new
clients who retained for 60 days. Retention scores were dichotomous. Those who did not
complete the 60 days were given scores of 0, and those who retained for 60 days were given
retention scores of 1.
Before the main statistical analyses were performed, all the variables of interest were
examined through SPSS for accuracy of data entry and to identify any missing values, the
normality of distributions, and multivariate outliers. Additionally, means, standard deviations,
skewness, and kurtosis were computed for each of the study variables and for the descriptive
variables in the sample. Pearson correlation coefficients were calculated to address the two study
hypotheses. Finally, logistic and multiple regression analyses were conducted to examine how
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much of the variance in each of the two dependent variables (recovery quality and treatment
retention) could be explained by each of the predictor variables (hope agency, hope pathways,
grit, and readiness to change).
Participant Demographics
Participant demographics were reviewed after data screening. All participants identified
as Caucasian, which can be somewhat attributed to the population demographic in the area;
however, research from buprenorphine programs nationwide reflect a disproportionately higher
rate of Caucasian participation compared to the local ethnic population mix (Hansen et al.,
2013). Data on age, gender, education level, marital status, and employment status are shown in
Table 1.
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Table 1
Participant Demographics
Characteristic

n

%

18–24

4

12.9

25–34

11

35.5

35–44

9

29.0

45–54

7

22.6

Male

20

64.5

Female

11

35.5

Some high school

5

16.1

High school graduate

17

54.8

Some college

7

22.6

Bachelor of arts/bachelor of science degree

2

6.5

Married/partnered

13

41.9

Never married

12

38.7

Divorced

5

16.1

Widowed

1

3.2

Employed for wages

18

58.1

Out of work

4

16.1

Self-employed

4

12.9

Unable to work

5

12.9

Age range (in years)

Gender

Education level

Marital status

Employment status

Sample Means
Mean, median, mode and standard deviations were calculated for each measure for all
participants. Results were separated into three groups, including participants who were retained
in treatment for 60 days (n = 10), the group that did not retain in treatment (n = 6), and a group
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of participants surveyed who had been in treatment 60 days when the trial began (n = 15).
Results are summarized in Table 2.
Table 2
Variable Statistics for Each Outcome Group
Group and measure

M

Mdn

SD

Readiness

3.80

4.00

0.632

Hope agency

21.00

19.00

5.454

Hope pathway

23.20

25.00

5.493

Grit

37.50

37.00

7.835

Recovery quality

52.40

53.00

4.169

Readiness

3.83

4.00

0.408

Hope agency

17.67

17.00

5.680

Hope pathway

19.38

18.00

5.456

Grit

36.67

36.00

7.840

––

––

––

––

––

––

Hope agency

26.20

27.00

5.454

Hope pathway

26.67

27.00

5.314

Grit

43.73

43.00

7.156

Recovery quality

57.13

58.00

5.854

Retained in treatment (n = 10)

Not retained in treatment (n = 6)

Recovery quality
In treatment 60 days when trial began (n = 15)
Readiness

Means and standard deviations for each of the four independent variables and recovery
quality were calculated for each group. The existing treatment group had higher mean scores for
hope agency, hope pathways, and grit than did the other two groups, and as expected, the
retained in treatment group had higher scores in hope agency, hope pathways, and grit than the
group that did not complete treatment. These results are shown in Table 3.
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Table 3
Descriptive Statistics for Each Group by Variable
Variable
Hope agency
Group

Hope pathways
SD

Grit

M

SD

M

M

SD

Retained in treatment (n = 10)

21.00

5.45

23.20

5.49 37.50 7.84

Not retained in treatment (n = 6)

17.67

5.68

19.83

5.46 35.67 7.84

In treatment 60 days when trial began
(n = 15)

26.20

5.45

26.67

5.31 43.73 7.16

Participants in the group that did not complete treatment (n = 6) did not have quality of
recovery scores. The group of existing participants (n = 15) had higher mean scores (57.13, SD =
5.85) in quality of recovery than did the new participants (n = 10) who completed treatment (M =
52.40, SD = 4.17). Longer recovery time allowing for continued improvement could account for
the higher quality score.
Data Analysis
Data analysis was performed using SPSS. Participants completed all measures with a
counselor, so all the items for each measure were completed, and no one was excluded from the
analysis. Multivariate correlations were completed between the dependent variable of recovery
quality and independent variables of hope agency, hope pathway, and grit for the group of 25
participants who completed treatment (15 in treatment for 60 days at the time of the study, 10
new enrollments who remained in treatment for 60 days at study completion). Simultaneous
multiple regression analyses were completed to examine how much of the variance in recovery
quality was explained by the three predictor variables––hope agency, hope pathway, and grit––
for the two groups (n = 15 and n = 10). A logistical regression analysis was completed to
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determine how well the four independent variables of hope agency, hope pathway, grit, and
readiness to change could predict the dichotomous dependent variable of treatment retention for
60 days for the 16 participants who began treatment during the study. This was a pilot study with
a small sample size, so none of the results can be considered statistically significant. The data
from these analyses are presented next.
Correlations
Pearson correlations were completed for the 25 participants retained in treatment to
determine the relationship between scores for recovery quality, hope agency, hope pathway, and
grit. The analysis suggested positive correlations between recovery quality and hope agency
(r = .733, p < .01), hope pathway (r = .583, p < .01), and grit (r = .658, p < .01). These results
suggested that the subjects who were retained in treatment and who indicated higher levels of
hope agency, hope pathway, and grit tended to have higher quality of recovery scores. Therefore,
the null hypothesis for RQ1 was rejected for this group of participants.
Simultaneous Multiple Regressions
Simultaneous multiple regression analysis was conducted to determine how much of the
variance in recovery quality reported by the 25 subjects who successfully retained in treatment
for 60 days could be explained by the three predictor variables: hope agency, hope pathway, and
grit. The original intention was to include readiness scores; however, there were 15 missing cases
for this variable, so it was eliminated from this regression equation. These 15 cases represented
individuals who had already successfully completed 60 days of treatment, so their readiness
scores were not relevant. See Table 4 for analysis of variance (ANOVA) results and the
significance level for this experimental sample. The three independent variables accounted for
54% of the variance in recovery quality, R2 = .54, adjusted R2 = .475, F(3, 21) = 8.230, p < .001.
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The results indicated that for this small sample size, the model was a predictor of recovery
quality scores (R = .735, R2 = .540, adjusted R2 = .475, SEE = 4.107). Of the three independent
variables, hope agency accounted for most of the variance in recovery quality (b = .599). The
null hypothesis for Question 1 was rejected for this group (n = 25), as hope agency, hope
pathways, and grit were predictors of recovery quality scores in this limited sample. These
results are consistent with research correlating hope (Marcovitz et al., 2016) and grit (Griffin et
al., 2016) with successful treatment outcomes.
Table 4
Quality of Recovery Regression (Analysis of Variance) Results (n = 25)
Model

Sum of squares

df

Mean square

F

Regression

416.399

3

138.800

8.230

Residual

354.161

21

16.865

Total

770.560

24

Sig.
.001

Simultaneous multiple regression analysis was conducted to determine if higher readiness
to change scores were predictive of higher recovery quality scores.. The regression equations
used the four predictor variables––hope agency, hope pathways, grit, and readiness to change––
to predict the outcome variable of recovery quality. Readiness scores could only predict recovery
quality for the 16 participants who began treatment in the study, and only 10 completed
treatment, so n = 10. The other 15 came into the study as existing clients and were not reflected
in this analysis. See Table 5 for analysis results. This sample’s smaller size was a factor in lack
of statistical significance. The null hypothesis for RQ1 was not rejected for this group.
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Table 5
Quality of Recovery Regression (Analysis of Variance) Results (n = 10)
Model

Sum of squares

df

Mean square

F

Regression

45.091

4

11.273

.506

Residual

111.309

5

22.262

Total

156.400

9

Sig.
.735

Logistic Regression
Finally, the null hypothesis for RQ2 (Can hope agency, hope pathways, grit, and
readiness to change scores predict treatment retention) was examined for the 16 new clients
(retained in treatment, n = 10, not retained in treatment, n = 6) for treatment retention for 60
days. A logistic regression was used to investigate how well each of the four independent
variables of hope agency, hope pathway, grit and readiness to change could predict the
dichotomous dependent variable of treatment retention for 60 days. The results of the logistic
regression showed that none of the independent variables were significant (p > .05). The null
hypothesis for RQ2 was not rejected.
Chapter Summary
The statistical analyses for this study were reported in this chapter. The data screening
process was presented, then subject demographics were detailed. Descriptive statistics were
separated into groups and presented. Then a correlation, multiple regression models, and a
logistical regression model were presented to test the hypotheses for the two research questions.
The null hypothesis for RQ1 was rejected for hope agency, hope pathways, and grit as they were
predictors of recovery quality scores. The null hypothesis for RQ1 was not rejected for readiness
scores. The null hypothesis for RQ2 was not rejected as none of the independent variables had an
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effect on treatment retention for 60 days. Although not statistically significant, the correlation
between hope agency (r = .733), hope pathways (r = .583), grit (r = .658), and recovery quality
was encouraging. Further review of the study’s statistical implications, conclusions, and
recommendations are in the following chapter.
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CHAPTER FIVE: SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
The purpose of this study was to examine the relationship of personal characteristics of
hope agency, hope pathways, grit, and readiness to change with the efficacy of medicationassisted treatment (MAT) for opioid use disorder (OUD) delivered in an office-based
buprenorphine program. Participants entering the program during the study completed the Adult
Hope Scale (AHS), the Stages of Change Readiness and Treatment Eagerness Scale
(SOCRATES): Drug Version 7D, and 12-Item Grit Scale (Duckworth et al., 2007) in order to
quantify these three personal characteristics. Each participant was evaluated after 60 days for
treatment retention and quality of recovery. Recovery quality was assessed for those still in
treatment using the Substance Abuse Recovery Evaluator (SURE; Neale et al., 2016).
Problematic opioid use has occurred for centuries (Corrigan et al., 2017). Recent
treatment methods include abstinence-based strategies and medication-assisted harm reduction
programs such as methadone treatment (Hser et al., 2014). Office-based buprenorphine programs
have gained traction as an effective treatment process, especially since 2010 as the recent opioid
epidemic has spiked (Blum et al., 2016). The present study focused on identifying predictors of
treatment retention and recovery quality in office-based buprenorphine programs.
The data analysis results were presented in Chapter Four. Chapter Five includes
additional findings and their implications. This chapter also provides a discussion of the study’s
two research questions. Limitations of the study, implications for practice, and suggestions for
future research are also reviewed in this chapter.
Summary of Findings and Implications
The study participants were recruited from an office-based outpatient buprenorphine
treatment program for OUD from September 19, 2019 to December 31, 2019. A sample of 31
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participants was obtained during data collection. They were categorized as new or existing
clients and the appropriate assessments were provided. The participants were all Caucasian, ages
18–54 years. Most were male (64.5%), married or partnered (41.9%), employed (58.1%), and
high school graduates (54.8%). Two research questions were addressed in this study and are
discussed next.
Research Question 1
The first research question asked if hope agency, hope pathways, grit, and readiness to
change scores were predictive of recovery quality scores. A regression analysis on a group that
combined new and existing clients who remained in treatment supported the variables of hope
agency, hope pathways, grit being predictive of recovery quality. These three independent
variables in this analysis accounted for 54% of the variance in recovery quality. A secondary
analysis suggested positive correlations between recovery quality and hope agency (r = .733),
hope pathway (r = .583), and grit (r = .658). These results were somewhat expected since the
literature has shown hope (Bradshaw et al., 2014) and grit (Duckworth, 2016) to be predictive
traits in various types of successful outcomes. Though not significant statistically due to the
small sample size in this pilot study, the results are encouraging for future researchers to further
explore.
A second analysis that reflected new clients only who completed treatment included the
fourth predictor variable, readiness to change. This analysis did not support readiness to change
as a predictor of recovery quality, as all four independent variables accounted for only 29% of
variance in the analysis for this group. Fewer reportable participants accounted for some of this
finding, but readiness to change mean scores were slightly higher for those who did not complete
treatment than for those who did (3.83 versus 3.80). Mean scores for the other three predictor
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variables were higher for those who completed compared to those who did not. Hope and grit are
traits, while readiness is a present state of mind (DiClemente, 2018). Research has indicated that
readiness to change can be predictive of treatment outcomes (Connors et al., 2013), but these
findings did not support this research.
Research Question 2
The second research question asked if hope agency, hope pathways, grit, and readiness to
change scores were predictive of treatment retention. All four predictor variables combined only
accounted for 18% of the variance in retention, suggesting that they did not predict treatment
retention. A linear regression analysis for the group of new treatment participants indicated that
none of the independent variables were significant in predicting treatment retention. Despite
increased research on OUD treatment (Martin & Finlayson, 2015) and demographic/situational
predictors of success (Thomas et al., 2013), there appears to be limited research regarding the
effect of personality characteristics and traits on treatment success. Unfortunately, recovery
quality scores were not obtainable from those who did not complete treatment, so the effect of
dropout on recovery quality score could not be determined for this group. However, research has
indicated that treatment retention is a predictor of higher recovery quality (Meier et al., 2014).
Limitations of the Study
Sample size was the first limitation in this study. The assumption was that there would be
no interruption in services provided in the office-based buprenorphine program. However, the
program’s main prescriber left the practice early in the study to relocate out of state. Since the
study had already started, it was continued. The assumption was that the study would include
many more participants. Because it did not, the sample size was less relevant, especially for
predicting treatment retention. Also, the data were possibly less representative of the population
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and therefore less generalizable to other populations. Future research on this topic would benefit
from larger sample sizes, which could be attained by involving several prescribers to minimize
the possibility of a reduced participant pool.
Another study limitation was that all 31 participants were Caucasian. However, national
surveys of medication-assisted treatment (MAT) program patients have indicated that
buprenorphine patients were more likely to be Caucasian (92%) as compared to 53% of
methadone program patients (Main & Kelly, 2016). Even in ethnically and racially diverse New
York City, buprenorphine treatment was found to be unevenly distributed to Caucasian
populations (Hansen et al., 2013). In this current study, only those with health insurance
(including Medicaid) or the ability to self-pay were included, which could be an economic
limitation, but including Medicaid recipients seems to balance out the participants’ overall
socioeconomic status.
Regrettably, participants who did not complete treatment had no recovery quality scores.
This methodology deficiency could have been corrected with specific effort to gather the data by
attempting to follow up with these clients and obtain a quality score after 60 days, even though
the participants had left the program, instead of just having no score. This deficiency could be
corrected in future research efforts.
Another limitation in this study was the assumption that the instruments measured what
they were intended to measure. All four assessments have support for their reliability and
validity, but their reliability and validity remain an assumption. Also, the AHS and the Grit Scale
have only 12 questions each, while the other two instruments are more robust. Future research
could consider additional scales for further support and clarity.
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A conceptual limitation of this study was the likelihood that the predictive variables used
did not include all relevant elements of predicting treatment retention and quality of recovery for
office-based opioid treatment clients. Also, the variables that were used––hope, grit, and
readiness to change––can be influenced by situational variables such as current quality of
intimate relationships, pending legal issues, or physical health. Comorbid mental health
diagnoses were not taken into consideration and could have influenced client responses (see
Heikman et al., 2017).
Another limitation was that all four instruments used are self-report, so the information
cannot really be independently verified and must be taken at face value. Participants could have
misinterpreted the questions or misunderstand some of the terminology, or there could be biases
such as selective memory, exaggeration, or social desirability bias (see Van de Mortel, 2008).
Also, with the addicted population, the possibility of any level of impairment could skew survey
responses (DiClemente et al., 2017).
Suggestions for Future Research
Gaps in the literature regarding individual traits and states and office-based opioid
buprenorphine treatment retention and recovery quality were addressed in this study. Research is
available on demographics and other physical and situational variables as predictors of substance
abuse treatment results (Stein et al., 2015), but few studies have included individual traits in
office-based MAT. As opioid use continues to be a global public health epidemic (Thomas et al.,
2013), future research should continue to pursue the importance of these variables and others
related to opioid treatment and recovery to better understand the possibilities for improved
outcomes. A future research possibility could be to validate the present study’s findings to
determine if these characteristics are predictive of treatment outcomes in other OUD populations.
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A larger sample size would be greatly beneficial in gaining further understanding of
treatment predictors and outcomes. Obtaining a larger sample could be accomplished by using
multiple prescribers and/or facilities to secure more study participants and a more diverse
population. This study was confined to 60 days, whereas a longitudinal study covering 6 or 12
months could provide additional data for a greater effect size. Conducting a mixed methods
study could also yield more robust data and additional relevant information regarding treatment
retention and recovery.
Future research could also include gathering follow-up data from participants who do not
complete treatment. More thoroughly investigating the circumstances of individuals who do not
continue in treatment could reveal significant information in unsuccessful outcomes. This
research could provide greater insights into addressing client deficits at the beginning of
treatment for improved retention. A more individualized treatment plan can greatly improve the
probability of a successful outcome (Dhawan & Chopra, 2013; Heikman et al., 2017).
Future research measuring other traits of individuals in opioid treatment programs could
also provide broader predictive data. For example, God concept, honesty, adaptability, or
emotion regulation skills could influence treatment outcomes (Oberleitner et al., 2019).
Comorbid mental diagnoses, psychiatric stress, and dependence severity and history, as well as
chronic pain, which is often present in OUD, are also measurable risk factors for treatment
(Rogers et al., 2019). The individual participant’s life circumstances and situations that may also
affect treatment outcome, such as life stress or abuse history could be measured and lend insights
on positive or negative recovery results (Tate et al., 2005). Psychosocial intervention data can be
further studied as a predictor of OUD recovery (Anyimukwu & Omondi, 2020). Additionally,
future research could examine treatment retention and recovery quality across social and
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economic measures. All these differences could be investigated to help gain greater insights into
predictive characteristics of treatment success or failure. Using integrative models that consider
biological, psychological, social, and spiritual dimensions could be beneficial for providing a
deeper understanding of clients’ predictive needs.
The field of performance measurement continues to progress, as does the availability of
MAT programs, particularly office-based buprenorphine prescribers, to treat OUD (Thomas et
al., 2013). This is encouraging, as the number of individuals with OUD diagnoses continues to
increase (Yang et al., 2020). Findings from the current study and future research on predictors of
treatment retention and recovery quality could be beneficial for individuals entering OUD
treatment programs and possibly for other mental health disorder treatment. Therefore, there is
benefit for future research on personal traits as predictive factors influencing OUD treatment
outcomes.
Clinical Implications
This pilot study has important clinical implications for counselors in several areas. The
findings showed a pattern of better recovery quality for participants with higher hope and grit
scores. If this study can be further validated and generalized to other OUD populations, the
assessments employed in this study could be used to examine these characteristics of interest
before entering treatment to determine individual strengths and weaknesses in these areas.
Hopelessness and lack of perseverance and motivation can be significant barriers to successful
treatment outcomes (Duckworth, 2016). Having this predictive information would provide
counselors with relevant prognostic information to influence treatment planning to address
deficits as needed, as well as to cultivate client strengths. Based on these scores, counseling and
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even prescriber visit frequency could be scheduled appropriately. This would make treatment
more personal and, at the same time, more evidence based.
A clinical implication of this study for counselors would be that lower scores in these
assessments could be indicative of other mental health disorders such as depression, anxiety,
posttraumatic stress disorder, etc. Comorbid diagnoses can complicate treatment efforts and can
be a barrier to successful outcomes (Meier et al., 2014). However, co-occurring disorders can be
even more problematic if not addressed. The substance abuse population is one with a high rate
of comorbidity (Weiss et al., 2011), so identifying this condition can improve the probability of a
better treatment outcome.
Another counseling implication could be the self-awareness clients could gain from the
results of these assessments. These results could help clients recognize the connection between
change and the increased probability of a positive treatment outcome. This insight to self could
motivate clients to take ownership of the change needed to overcome a potential hindrance to
treatment. Personal adjustment in these areas is possible even though grit and hope are traits and
not states.
Much still needs to be learned about how to best utilize office-based buprenorphine
treatment for OUD. But if these characteristics can be identified at the beginning of treatment,
and addressed, clients may be more able to achieve a potentially better recovery outcome.
Heikman et al. (2017) stated that treatment success can significantly vary depending on certain
individual attributes. This is relevant not only at treatment outset but also for therapeutic gains
achieved to be maintained after treatment ends. The study findings should be applied in clinical
practice.
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Summary of Chapter
This chapter was a summary of the study findings and limitations, clinical implications,
and recommendations for future research. As an exploratory study, the sample size was too small
to establish statistical significance. Three main findings were discussed in this chapter. First,
there was a positive correlation between recovery quality and hope agency (r = .733), hope
pathway (r = .583), and grit (r = .658). Further analysis showed that the three independent
variables accounted for 54% of the variance in recovery quality. Second, contrary to findings in
previous studies, no relationship was found between readiness to change and recovery quality.
This may be partially attributed to a smaller sample size and other factors discussed in the
limitations section. Third, hope agency, hope pathways, grit, and readiness to change scores were
not predictive of treatment retention.
The study limitations included a small sample size, limited racial/ethnical diversity, the
data collection procedures and methods, and self-reported information. Future research should
include larger sample sizes and other populations and demographics. Qualitative methods for
more robust insight and exploring other factors that could predict treatment retention should also
be considered. Counseling implications include recognizing the impact of identifying personal
characteristics at treatment outset to inform treatment planning that compensates for patient
deficits and uses their strengths. Identifying these traits may also reveal other mental health
conditions as well as provide self-awareness for motivation to clients.
Summary of Study
An investigation of extant literature indicated a connection between hope, grit, and
readiness to change with successful outcomes. Few studies have focused on these three
individual characteristics for treating individuals diagnosed with OUD in office-based
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buprenorphine programs. The study focus was on determining if these characteristics would
predict treatment outcomes. Study participants were recruited from a large practice facilitating
this treatment. All 31 participants were retained after screening. Correlation and regression
models showed hope agency, hope pathways, and grit to be predictive of recovery quality but not
treatment retention. Further analysis showed readiness to change to not be predictive of either
quality or retention. Future research on these characteristics and others of individuals
participating in office-based OUD treatment would be beneficial to provide further insights for
treatment planning for optimum outcomes. Clinicians can use this information to cultivate more
productive therapeutic relationships. Despite the small sample size and lack of statistical
significance in this pilot study, these results are encouraging and important clinically and for
future research.
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APPENDIX G: Recruitment Letter
Greetings,
I am inviting you to participate in a clinical study.
John Pulliam, a doctoral candidate in the Department of Counselor Education and Family Studies
at Liberty University, is conducting this study. I am conducting research to better understand
predictors of success in an outpatient buprenorphine program. The purpose of my research is to
measure the personal characteristics of hope, grit, and readiness to change in relation to treatment
retention and quality of recovery.
Since you are seeking this specific treatment, you are eligible to participate. If you are willing,
you will be asked to:
1. Complete the Adult Hope Scale, Grit Scale, and Socrates 7D at program enrollment/first
visit. This will take between 20-60 minutes
2. Complete Substance Use Recovery Evaluation Scale at next visit after 60 days enrolled.
This will take between 15-30 minutes
This information will be completely anonymous and will remain confidential.
To participate, first review and sign the attached consent document, which contains additional
information about the research. Then, complete the attached three questionnaires, which we will
collect and file in your confidential chart. We will do these in session, so the counselor can
answer any questions you may have. On your next visit after 60 days in the program, you will
complete the final questionnaire.
Thank you for participating. The information gathered in this study could help to improve
treatment outcomes.
Sincerely,

John Pulliam MA, LPC, LCAS, CCS

